Viking Therapeutics Inc (VKTX)

[DMOST]

NASH Opportunity Driving Growth for Viking Therapeutics in 2018

NASH Opportunity Driving Growth for Viking Therapeutics in 2018
By Margaret PatrickOct 19, 2018 | 9:55 PM

Positive news and target price revisions

On September 18, Viking Therapeutics (VKTX) announced its positive top-line results from its Phase 2 study evaluating its investigational therapy, VK2809. This study evaluated reduced LDL-C levels and reduced fat content in patients who have nonalcoholic fatty liver disease (or NAFLD) and high LDL-C levels.

After this announcement, H.C. Wainwright issued a “buy” recommendation for the company and increased the 12-month target price from $15.00 to $28.00. Maxim Group also issued a “buy” recommendation and increased its target price for Viking Therapeutics from $14.00 to $28.00. Raymond James issued an “outperform” recommendation and increased its 12-month target price for Viking Therapeutics from $15.00 to $43.00 on September 18........
https://marketrealist.com/2018/10/nash-opportunity-driving-growth-for-viking-therapeutics-in-2018?utm_source=yahoo&utm_medium=feed&yptr=yahoo

GO VKTX

"PEACE"